Overview

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of AGG-523 in healthy subjects and in subjects with osteoarthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer